An Updated Analysis of Pembrolizumab (MK-3475) for Melanoma
Jedd D. Wolchok, MD, PhD, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma.
Clinical Pearls
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma. These data were presented by Dr. Antoni Ribas.
- 72% of patients experienced at least disease control.
- As of the last data analysis, 88% of patients who had responded were experiencing a continued response.
- This is characteristic of immunotherapy the effects of the medicine on the immune system should lead to durable control of the disease.
<<<
Related Videos
Related Content
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Article
Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
